Impact Factor
3.58
Journal Citation Impact
Estimated influence, citation density, publishing volume, and citation integrity from the analytics table.
Citation rate
3.99
287 total citations
h5-index
26
h5 depth signal
Cited share
77.0%
57 of 74
Total citations
287
Citation footprint
Metric signal
7.72
External metric anchor
Self-citation
2.1%
6 self-citations
Citations Trend
Monthly Publications Cadence
Citing Geographic Demographics
China
217
India
121
United States
66
Iran
29
Saudi Arabia
21
Citing Fields of Research
Noncoding RNA
82
Genetics & Genomics
79
Stem Cell Biology
75
Immunology
64
Cancer & Development
58
Publishing Activity & Reach
Volume, recency, access pattern, and citing-community signals from the journal analytics record.
All-time article footprint
1,267
Articles tracked across the journal lifetime
Indexed publication set
74
57 cited publications
Last 12 months
111
10.1 publications/month
Open access share
2.7%
3 OA publications in the last year
Leading citing country
China
217 citing publications
Leading citing field
Noncoding RNA
82 citing publications
Latest tracked publication
14 October 2026
10 recent records available
Coverage & Indexing History
v1n1, May 2001-
v1n1, May 2001-
Active Coverage
Research Focus & Classification
Indexed Subjects
Immunology
Genetics & Genomics
Noncoding RNA
Oncology
Cancer & Development
Neurodegenerative Disorders
Broad Categories
Genetics, Medical
Therapeutics
Noncoding RNA
Genetics & Genomics
Immunology
Viral Identification & Phylogenetics
Neurodegenerative Disorders
Polymer & Macromolecule Science
MeSH Descriptors
Gene Transfer Techniques
Genetic Therapy
Latest Publications
Recent article records with DOI-first linking and condensed abstracts.
01
DOI 10.2174/0115665232489928260716120134
Open DOI
Effect of Source and Time of Collection on rAAV9 Production Yield and Quality: A Comparative Bioprocess Analysis
Introduction: A comprehensive analysis of Critical Quality Attributes (CQAs) is crucial for extended culture conditions across sources and time points. Methods: The rAAV9-eGFP vectors were produced. Further, collected lysates and culture...
02
DOI 10.2174/0115665232501139260924083439
Open DOI
SMART Nanocarriers for siRNA Delivery: Stimuli-Responsive Platforms for Targeted Gene Silencing
Despite the remarkable specificity of small interfering RNA (siRNA)-based treatments for gene silencing, biological limitations like poor stability, rapid systemic clearance, immunogenicity, and inefficient intracellular delivery hinder ...
03
DOI 10.2174/0115665232513137260921053855
Open DOI
MicroRNA Therapeutics in Cancer: Revisiting the Promise and Understanding the Limitations of Clinical Translation
MicroRNAs (miRNAs) have emerged as promising therapeutic agents in cancer because of their ability to simultaneously regulate multiple oncogenic pathways and gene networks. Early preclinical studies demonstrated substantial anti-tumor ac...
04
DOI 10.2174/0115665232398321251118011107
Open DOI
Gene-Driven Precision Medicine: Enhancing Biomarker Identification for Personalized Therapy
Transformative advances in biomarker science are reshaping the landscape of precision medicine, offering powerful tools for early disease detection, accurate prognostication, and individualized therapeutic design. This review synthesizes...
05
DOI 10.2174/0115665232507240260910050841
Open DOI
Identification of CDKN1A as a Candidate Therapeutic Target in Peripheral Artery Disease Progression: Integrative Multi-omics and Mendelian Randomization Study
Introduction: Therapeutic strategies for advanced Peripheral Artery Disease (PAD), including angiogenic gene therapy trials, have yielded limited clinical benefit, partly because target selection has relied on empirical biological reason...
06
DOI 10.2174/0115665232472718260908102938
Open DOI
PSKH1: A Promising Therapeutic Target in Prostate Cancer, Mechanisms and Potential Interventions
Cancer of the prostate is an important issue on a global scale, and therefore the identification of targets to support the development of therapy for this cancer should be a priority, particularly given the rise in cases of advanced pros...
07
DOI 10.2174/0115665232515473260910071847
Open DOI
Trends and Hotspots in the Convergence of Artificial Intelligence and Cell and Gene Therapy: A Patent Analysis
Introduction: The convergence of Artificial Intelligence (AI) and Cell and Gene Therapy (CGT) represents a frontier in next-generation therapeutic innovation, yet the structural patterns of technology convergence within this interdiscipl...
08
DOI 10.2174/0115665232436545260906074748
Open DOI
Artificial Intelligence-Driven Gene Delivery Systems in Dementia: A Comprehensive Review of Mechanisms, Tools, and Therapeutic Strategies
Introduction/Objective: The progressive nature of dementia is represented by a reduction in two or more cognitive functions, including language, memory, executive and visuospatial functioning, personality, and behavior. Only symptoms can...
09
DOI 10.2174/0115665232491924260907063026
Open DOI
Prime Editing and Its Delivery: Recent Advances in Gene Correction for Genetic Diseases
Prime editing (PE), as a transformative genome-editing technology, overcomes many of the limitations of CRISPR-Cas9, particularly by enabling high-fidelity base conversions independent of double-strand breaks (DSBs). This unique mechanis...
10
DOI 10.2174/0115665232473217260821092300
Open DOI
Nanocarrier-Mediated Nucleic Acid Therapy in Non-Small Cell Lung Cancer: Converging Delivery Barriers, Resistance Reversal, and Clinical Translation
Background: Lung cancer remains a leading cause of cancer-related mortality worldwide, and non-small cell lung cancer (NSCLC) is the major histological subtype. Although chemotherapy, molecular targeted therapy, and immune checkpoint blo...
Bibliographical & Catalog Notes
Description based on: Vol. 1, no. 3 (Sept. 2001); title from cover.
Vol. 1 complete in 4 issues.
Also issued online.